Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Expands By 49.4%

Aadi Bioscience, Inc. (NASDAQ:AADI) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 706,400 shares, an increase of 49.4% from the January 15th total of 472,700 shares. Approximately 3.5% of the shares of the company are sold short. Based on an average trading volume of 357,800 shares, the days-to-cover ratio is currently 2.0 days.

Institutional Investors Weigh In On Aadi Bioscience

A number of institutional investors have recently modified their holdings of AADI. BML Capital Management LLC bought a new stake in shares of Aadi Bioscience in the third quarter valued at about $4,120,000. XTX Topco Ltd bought a new stake in shares of Aadi Bioscience in the third quarter valued at about $32,000. Peapod Lane Capital LLC bought a new stake in shares of Aadi Bioscience in the fourth quarter valued at about $1,397,000. Geode Capital Management LLC boosted its position in shares of Aadi Bioscience by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 217,294 shares of the company’s stock valued at $686,000 after acquiring an additional 8,546 shares during the period. Finally, QVT Financial LP bought a new stake in shares of Aadi Bioscience in the fourth quarter valued at about $7,300,000. Institutional investors own 52.08% of the company’s stock.

Aadi Bioscience Stock Performance

Shares of Aadi Bioscience stock opened at $2.59 on Friday. The firm has a 50-day moving average of $2.91 and a 200-day moving average of $2.25. The stock has a market cap of $63.97 million, a PE ratio of -1.14 and a beta of 0.64. Aadi Bioscience has a 52-week low of $1.21 and a 52-week high of $3.81.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.